Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.37 |
| ▸ | PTGDR | Q13258 | 11/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 9/20 | 0.37 |
| ▸ | F10 | P00742 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL733788 | 1.00 | SCN9A (0.39) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734417 | 0.96 | PTGDR2 (0.37) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734418 | 0.96 | PTGDR2 (0.37) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734410 | 0.95 | SCN9A (0.37) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734411 | 0.95 | SCN9A (0.37) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734332 | 0.94 | F10 (0.41) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL732254 | 0.94 | PTGDR2 (0.37) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734331 | 0.94 | F10 (0.41) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL734604 | 0.94 | PTGDR2 (0.36) | SCN9APTGDR2PTGDRTBXA2RF10 | |
| SCHEMBL732253 | 0.94 | PTGDR2 (0.37) | SCN9APTGDR2PTGDRTBXA2RF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | claimed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | claimed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | claimed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420675-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2013-04-16 | — | — | US | disclosed |
| EP-2307383-B1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HOFFMANN LA ROCHE (CH) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | CHEN LI (CN) | 2012-04-26 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138208-B2 | Aminotetrahydroindazoloacetic acids | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | CHEN LI | 2010-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101131-A1 | Aminotetrahydroindazoloacetic Acids | HRH2, HRH1, HRH4 | SCN9A 2017/4885PTGDR2 16/4885PTGDR 12/4885 |
| US-20100016369-A1 | AMINOTETRAHYDROINDAZOLOACETIC ACIDS | HRH2, HRH1, HRH4 | SCN9A 2017/4885PTGDR2 16/4885PTGDR 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.